MedWatch

Combigene co-founder: The time has come for gene therapy

New study data and gene therapy have brought the Swedish biotech company Combigene a great step closer to a phase I study with its epilepsy candidate. However, the company needs to raise more capital to take the product to the market and a potential solution is a collaboration agreement with big pharma.

Foto: Combigene, PR

On August 30 this year, the commercialization of gene therapy – a treatment method that has been predicted a great future – passed a milestone.

That day, for the first time ever, the US Food and Drug Agency (FDA) approved of a gene therapeutic drug on the US market and thus clearly indicated the enormous business potential of drug development with gene therapy – a treatment most likely will be much more prevalent in future, especially as the big pharma groups become aware of the use of genes for therapeutic treatment.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Selvtests til skoleelever er på lager – nyt udbud sat i gang

Der ligger antigentests klar på lager fra tidligere indkøb, og de dækker i første omgang behovet for selvtests til skoleelever, som Regeringen og KL forleden besluttede skal supplere de kommunale skolers testindsats. En nyt udbud er netop skudt i gang for at dække efterspørgslen, når lagrene er tømte, oplyser styrelse.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier